SCHEMBL7710216

SCHEMBL7710216

CCC(c1ccc2c(c1)NC(N)=C(C)O2)N(Cc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
ALOX5 P09917 1/20 0.32
ALOX15 P16050 1/20 0.32
HTR2C P28335 1/20 0.31
SLC6A4 P31645 1/20 0.31
BACE1 P56817 5/20 0.31
AKT1 P31749 2/20 0.31
ABCB1 P08183 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
SYK P43405 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7708174 0.88 GAA (0.37) L3MBTL1POLBALDH1A1LMNATRPM8
SCHEMBL6995053 0.84 POLB (0.34) HSD17B10L3MBTL1POLBALDH1A1LMNA
SCHEMBL7704922 0.81 PARP1 (0.48) HSD17B10L3MBTL1ALDH1A1HDAC3HDAC1
SCHEMBL7088859 0.81 PARP1 (0.37) HSD17B10L3MBTL1POLBALDH1A1LMNA
SCHEMBL7704910 0.81 HDAC1 (0.45) HSD17B10ALDH1A1HDAC3HDAC1HDAC2
SCHEMBL7710218 0.75 HTR2C (0.33) HSD17B10L3MBTL1POLBALDH1A1LMNA
SCHEMBL7711366 0.74 HDAC1 (0.37) ALDH1A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7708189 0.74 HDAC3 (0.37) HSD17B10POLBALDH1A1LMNAHDAC3
SCHEMBL6302692 0.73 BRD4 (0.38) L3MBTL1POLBHDAC3HDAC1HDAC2
SCHEMBL7708353 0.72 GRM2 (0.37) ALDH1A1LMNAHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed